07:53 AM EDT, 05/29/2024 (MT Newswires) -- Merck & Co. ( MRK ) said Wednesday that the US Food and Drug Administration has accepted for priority review the supplemental biologics license application of its Keytruda drug in combination with chemotherapy to treat patients with malignant mesothelioma, a type of cancer in the linings of certain parts of the body.

The FDA has set a target action date of Sept. 25.

Merck's ( MRK ) application is based on data from a phase 2/3 trial, which showed statistically significant improvement in overall survival of patients treated with the treatment compared to chemotherapy alone.